U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06797479) titled 'Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients.' on Jan. 22.
Brief Summary: Quantification of anti PD-1 mAbs in cancer patients is extremely important to monitor pharmacokinetics and effectiveness of immunotherapy. To detect the ICI mAbs in patients' blood plasma samples, we select three anti PD-1 mAbs (cemiplimab, dostarlimab and pembrolizumab) as prognostic biomarkers which will be quantified using different biochemical/analytical assays.
Study Start Date: March 01
Study Type: OBSERVATIONAL
Condition:
Gynecological Cancer
Immunotherapy
Intervention:
PROCEDURE...